SAN FRANCISCO, CA — April 16, 2026 — BioXgen today announced its open investment offering under Regulation Crowdfunding alongside a live investor webinar taking place on April 30, 2026, at 10:30 a.m. Pacific Time. The event will give investors, supporters, and members of the public an opportunity to see BioXgen’s cardiac patch demonstrated on a heart model and hear directly from the company’s leadership about development progress, regulatory milestones, and the path toward first-in-human use.
Each year, more than 500,000 Americans undergo open-heart surgery, and nearly half develop postoperative atrial fibrillation, or POAF, within days of their procedure. POAF remains the most common complication of open-heart surgery, yet there is currently no FDA-approved device designed to prevent it. BioXgen is developing a cardiac patch intended to address that unmet need at the surgical site, with clinical data the company cites showing a tenfold reduction in postoperative AFib rates.
The company reports that the device is fully developed and that its FDA pre-submission has been filed, marking an important step toward final regulatory review. During the webinar, Dr. David Skinner and Dr. John Konhilas will present the device on a heart model, explain its application during surgery, discuss the clinical rationale for the patch, and answer live questions from attendees about the technology and BioXgen’s investment opportunity.
“This is a chance for investors to see exactly what BioXgen has built and why we believe it could change the future of open-heart surgery,” said Dr. David Skinner, President and CEO of BioXgen. “We have moved beyond concept. The device is finished, the regulatory process is underway, and we are excited to open this next phase of growth to the community.”
BioXgen’s current community investment round is being conducted pursuant to Regulation Crowdfunding, giving eligible investors the opportunity to participate as the company advances toward FDA clearance and commercialization.
The webinar is designed to offer a closer look at the BioXgen device, the clinical problem it aims to solve, and the broader market opportunity around POAF prevention. Attendees will be able to see the product, learn more about the company’s progress, and ask questions about the investment offering in a live interactive setting.
To learn more about the offering, visit invest.bioxgen.life. To attend the webinar, register here: https://dnagency.lpages.co/bioxgen-device-reveal-and-investor-update/
Disclaimer: In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. BioXgen has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained here: https://invest.bioxgen.life/
Contact
Dr. John Konhilas
Founder & CSO
dr.konhilas@bioxgen.life
BioXgen
About BioXgen: BioXgen is a medical device company developing a cardiac patch to prevent post-operative atrial fibrillation, the leading complication following open-heart surgery. The company's approach is built on 15 years of peer-reviewed research in biological scaffold technology, published clinical data showing a 10-fold reduction in POAF incidence, and an active FDA 510(k) submission process. The company is raising its 2026 Community Investment Round under Regulation Crowdfunding through DealMaker Securities. For more information, visit https://invest.bioxgen.life/
